Fig. 7: A switch between ARID1A-BAF and ARID1B-BAF is required for a successful exit from pluripotency. | Nature Communications

Fig. 7: A switch between ARID1A-BAF and ARID1B-BAF is required for a successful exit from pluripotency.

From: Inability to switch from ARID1A-BAF to ARID1B-BAF impairs exit from pluripotency and commitment towards neural crest formation in ARID1B-related neurodevelopmental disorders

Fig. 7: A switch between ARID1A-BAF and ARID1B-BAF is required for a successful exit from pluripotency.

a Time-course immunoblot conducted using Control Line-1 during CNCC differentiation shows that ARID1A is active at the iPSC stage, and abruptly downregulated at day 1 of differentiation. ARID1A protein level is upregulated again after day 7, mirroring ARID1B’s downregulation at the same time point. Experiment repeated twice (different biological replicates). Marker bars display kDa. b ARID1A time-course immunoblot in the two patient lines. Experiment repeated twice (different biological replicates). Marker bars display kDa. c ARID1A immunoblot: both patient lines display aberrantly high ARID1A’s protein level at CNCC Day 5. Experiment repeated twice (different biological replicates). Marker bars display kDa. d ChIP-seq for ARID1A in the two control lines and the two patient lines at iPSC stage (day 0) and at CNCC Day 5. Spike-in normalized heatmaps are centered on the 5540 pluripotency enhancers. The UCSC screenshot shows ARID1A and ARID1B binding at a patient-specific ATAC-seq peak (chr19:18,050,000–18,100,000) in the control and patient lines at iPSC stage and at CNCC Day 5.

Back to article page